MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Catalyst Biosciences, Inc (NASDAQ: CBIO)
Organization & Developments: Catalyst Biosciences
Parents
Catalyst Biosciences, Inc (NASDAQ: CBIO)
Children
* Hemophilia
*Catalyst Biosciences, Inc (NASDAQ: CBIO) is a research and clinical development biopharmaceutical company focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems.
2018: Catalyst Biosciences: Highly Attractive Hemophilia Pipeline With Upcoming Catalysts, Yet Still Trading At Cash Value_seekingalpha.com
2018: Catalyst Biosciences: Rare Risk/Reward Opportunity_seekingalpha.com
2019: Catalyst's Upcoming Readout In Hemophilia Is A Good Opportunity_seekingalpha.com
2021: Checking In On Catalyst Biosciences
2022: Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate Update_catalystbiosciences
Developer of engineered proteases as protein therapeutics that attack targets which cause disease.
Hemostasis
Jumps
*Key People: Catalyst Biosciences
Finance & Acquisitions: Catalyst Biosciences